Clinical Trials Browser

Phase 2/3 × tislelizumab × 90 days × Clear all

NCT07131319 2026-02-02

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06312982 2026-01-13

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Locally Advanced Rectal Carcinoma